Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNTEGRATE: Ibrutinib + Prednisone in New Onset cGVHD
NCT02959944Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- May 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Pharmacyclics. Started May 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02959944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959944.